MEK inhibition may rescue MAPK-mediated immune suppression by increasing the expression of major histocompatibility complex class 1 (MHC-I) on tumor cells, resulting in increased tumor antigen recognition by T cells [9,11]. This evidence concerns the gene MAP2K7 and neoplasm.